BOSTON, April 5 /PRNewswire/ -- Leerink Swann & Company announced today that Andrew Oh has joined the investment banking firm as Director - Analyst, Equity Research. Most recently, Andrew was in Equity Research at JP Morgan Chase where he was a member of the Number 1 ranked Institutional Investor research team covering U.S. pharmaceutical companies. Mr. Oh will be covering large-cap pharmaceutical companies.
“Leerink Swann has built a stellar reputation for independent fundamental equity research in the health care sector,” said Jeffrey A. Leerink, CEO and Chairman of Leerink Swann & Company. “As we continue to expand upon our expertise in the industry, we are pleased to add analysts of Andrew’s ability to our award-winning Equity Research Department.”
“Large-cap pharma is a critical focal point of our equity research efforts,” said William Tanner, Director of Equity Research at Leerink Swann. “We believe Andrew will make a significant contribution toward elevating research on those companies to the next level and further solidify the firm’s presence as a leading health care boutique.”
Mr. Oh received his B.A. in Biology from Washington University in St. Louis and an MBA from The Kellogg Graduate School of Management at Northwestern University. He previously was an Equity Analyst - Specialty Pharmaceuticals and Biotechnology at Stifel, Nicolaus and Company, and upon graduating from Washington University he was a co-founder of a startup wound- healing research company.
About Leerink Swann & Company
Leerink Swann & Company is an investment banking firm that provides health care equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Health Care Facilities, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2003 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp is comprised of nearly 10,000 consultants who are practicing physicians, surgeons, and biomedical professionals. Leerink Swann & Company is a member NASD/SIPC.
Leerink Swann & Company
CONTACT: John I. Fitzgerald of Leerink Swann & Company, +1-617-918-4564
